Share Your Passion for Research with a New GenerationContinue reading
Arizonans will receive benefit from recently FDA-approved precision medicine clinical trial to fight deadly melanoma Continue reading
This year, ovarian cancer will claim over 125,000 lives worldwide. The deadly disease remains the fifth leading cause of cancer-related mortality in U.S. women, killing about 15,000 per year.
19 patients who are not eligible for a donor heart transplant will participate in the pivotal clinical study to evaluate the SynCardia Total Artificial Heart for permanent use.Continue reading
Capstone Therapeutics (OTCQB:CAPS) and its joint venture affiliate, LipimetiX Development, LLC (“JV”), announced today the completion of and results for its investigational AEM-28 (Apo E mimetic peptide) Phase 1b/2a human clinical trial in cholesterol and lipid reduction.Continue reading
Surgery Performed on 25-Year-Old Valley Man after Dirt Bike Accident
Neurosurgeons at Barrow Neurological Institute have implanted the world’s first scaffolding device into the spinal cord of a patient.
Perseverance and adaptability are requisite qualities in drug development.
June 25, 2014
San Diego, CA – Calimmune today announced encouraging safety data from its innovative gene-based stem cell therapy, Cal-1-being developed to help cure individuals infected with HIV. The company can now begin treating the second group of patients in the trial, which is being funded in part by a grant from the California Institute for Regenerative Medicine (CIRM).Continue reading
Insys Therapeutics, Inc. (INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its pharmaceutical cannabidiol (CBD) for the treatment of Lennox-Gastaut Syndrome, a rare pediatric-onset epilepsy.